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Patients demonstrating warm autoantibody specificity present 
serologic challenges for laboratory staff performing antibody 
identification in the blood bank. Autoantibody can be removed 
from plasma or serum by adsorption onto autologous red blood 
cells (RBCs) provided the patient has not been transfused in the 
previous 3 months. The adsorption process can be enhanced by 
enzyme pretreatment of autologous RBCs. Immunohematology 
2012;28:88–90.
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Principle
Performing pretransfusion testing in the presence of 
warm autoantibodies optimally reactive at 37°C presents 
serologic challenges when attempting to determine the 
presence of underlying clinically significant alloantibodies.1 
Warm-reactive autoantibodies may mask the presence of other 
antibodies because of their agglutination with all cells tested, 
including autologous red blood cells (RBCs). To determine the 
presence of clinically significant antibodies, the removal of 
autoantibody may be achieved by adsorption of patient plasma 
or serum with autologous RBCs.2–4 Allogeneic RBCs may be 
used for adsorption if the patient has been recently transfused 
or when the quantity of autologous RBCs is insufficient for 
autoadsorption.2
Indications
As circulating autologous RBCs are coated with 
autoantibody, antigen sites on the autologous cells may 
become blocked with immunoglobulin. To efficiently achieve 
autologous adsorption of warm-reactive autoantibodies, 
autoantibody must be dissociated from the RBC before 
the adsorption process.2 Autoantibody dissociation can be 
accomplished by several methods, including partial heat elution 
at 45°C, gentle heat elution at 56°C, a combination of 0.2 M 
dithiothreitol (DTT) and papain or ficin treatment, acid-EDTA 
treatment, ZZAP (a mixture of cysteine-activated proteolytic 
papain and DTT) treatment, and chloroquine diphosphate 
(CDP) treatment.5 (For specific procedures concerning 
these methods and reagents, see the applicable procedural 
reference documents or manufacturer’s package insert.) After 
dissociation of the autoantibody from the autologous RBCs, the 
antigen sites should be available for binding the autoantibody 
from the plasma or serum during the adsorption process.
To further enhance the adsorption process, autologous 
RBCs can be treated with proteolytic enzymes such as ficin or 
papain. This additional treatment enhances antibody uptake 
onto the autologous cells by cleaving some of the glycoprotein 
chains extending from the cell membrane, leading to improved 
accessibility of the antigens not removed by the dissociation 
method.4
Procedure
For papain or ficin (1%) treatment of RBCs, one volume 
of 1% cysteine-activated papain or 1% ficin is added to two 
volumes of packed RBCs. For example, if 2 mL of packed 


































• 1 mL graduated pipettes
• 37°C water bath
• Large bore test tubes




• Mix enzyme with packed red cells
• Incubate mixture
• Wash mixture to remove enzyme
• Centrifuge to pack the red cells
• Remove supernatant
Adsorption • Mix enzyme-treated cells with patient plasma/serum
• Incubate  the mixture
• Centrifuge the mixture
• Remove plasma/serum
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is incubated at 37°C for a predetermined time to allow 
for the most effective enzyme treatment. If commercially 
prepared enzyme is used, the manufacturer’s insert is used 
to determine the incubation time. If enzyme is prepared in-
house, qualification studies are performed to determine the 
appropriate treatment time.6
The enzyme-treated RBCs are washed with copious 
amounts of isotonic saline a minimum of three times, or until 
the supernatant saline is clear, to ensure complete removal of 
enzyme. The last wash is centrifuged a minimum of 5 minutes 
at 900 to 1000× g to completely pack the RBCs.7 This step 
is critical to achieve proper packing of RBCs and removal of 
maximum amounts of saline. To avoid plasma or serum dilution 
during adsorption, as much saline as possible is carefully 
removed after the final wash. This can be accomplished with 
suction using a small-bore pipette or filter paper.4
To perform adsorption, one volume of enzyme-treated 
RBCs is mixed with an equal volume of the patient’s plasma or 
serum. To enhance antibody uptake, the proportion of RBCs to 
plasma or serum can be increased. Adsorption is more effective 
if the area of contact between the RBCs and plasma or serum 
is large; use of a large-bore test tube (16 × 100 mm) increases 
the surface area and allows for optimum plasma or serum and 
RBC contact. The mixture is incubated at 37°C for 10 to 60 
minutes.4 The mixture is then centrifuged and the plasma or 
serum is carefully removed. If the harvested adsorbed plasma 
or serum will be used for additional adsorptions, disturbing 
the packed RBCs to achieve maximum plasma removal is 
acceptable. If, however, the harvested adsorbed plasma or 
serum will be used for antibody detection, the packed RBCs 
should not be disturbed in an attempt to recover additional 
plasma.
The number of adsorptions required to exhaust 
autoantibody from the plasma or serum is proportionally 
related to the strength of its  reactivity in plasma or serum; 
however, in some instances, additional adsorptions may be 
required to remove the antibody.7–9 If the original plasma or 
serum reactivity is 1+ with the indirect antiglobulin test (IAT), 
the first aliquot of adsorbed plasma or serum should be tested 
against group O reagent RBCs or direct antiglobulin test (DAT) 
negative autologous RBCs, if available. If reactivity persists, 
the adsorption procedure should be repeated, as needed, using 
a fresh volume of enzyme-treated RBCs. Once reactivity is 
abolished, the adsorbed plasma or serum is tested against the 
appropriate group O reagent panel RBCs to exclude underlying 
alloantibodies.
Limitations
A recently transfused patient (within the last 3 months) 
is not a candidate for autologous adsorption. Circulating 
transfused RBCs may adsorb clinically significant plasma or 
serum alloantibodies.2 It has been demonstrated that very small 
amounts of antigen-positive RBC are capable of eliminating 
alloantibody reactivity from the plasma or serum.2,10
Large volumes of autologous RBCs from the patient are 
needed to perform autoadsorption. In the case of a low patient 
hematocrit, it may be difficult to obtain a sufficient volume 
of autologous cells for testing without exacerbating clinical 
symptoms of anemia.
Cell treatment may be unsuccessful in stripping 
autoantibody from the autologous, coated RBCs. As a result, 
adsorption may be less efficient in removing autoantibody.
Enzyme treatment of RBCs will destroy antigen sites on 
the RBCs. Enzymes remove sialic acid from the RBCs and will 
destroy some antigens (-M, -N, -S, -s, -Fya, -Fyb, -Ena, -Ge, 
-JMH, -Ch/Rg, -Inb). Autoantibodies specific for enzyme-
sensitive antigens will not be removed by this method.4
Potential dilution of adsorbed plasma or serum must be 
considered a consequence of preparation of enzyme-treated 
cells. If the saline is not properly removed after the final wash, 
the residual saline will dilute the plasma or serum when 
adsorptions are performed. The more adsorptions performed, 
the greater the dilution factor. As a result, diluted antibody 
may become undetectable in the adsorbed plasma or serum.
Enzyme treatment of autologous RBCs can cause 
hemolysis. If the RBCs are hemolyzed by enzyme treatment, 
there may be an insufficient quantity of RBCs remaining to 
perform adsorptions.
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